Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Relmada Therapeutics, Inc. Common Stock

RLMD

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Last trade $3.04
Day change -$0.57 (-15.79%)
Day range $3.01 – $3.71
Volume 1,468,269
Market cap $385M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$385.17M
Price / earnings
—
Price / book
1.99×
Price / sales
—
EV / sales
—
EV / EBITDA
-5.59×

Profitability

Earnings per share
-$0.62
Return on assets
-32%
Return on equity
-33.91%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
26.37×
Quick ratio
26.37×
Cash ratio
0.74×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$51.86M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for RLMD, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$3.88M$6.62M$11.37M$12.26M$6.29M$7.4M$6.27M$8.08M
Research and development$9.22M$8.39M$8.09M$8.07M$4.04M$2.82M$11.95M$11M
Total operating expenses$13.1M$15.01M$19.46M$20.33M$10.33M$10.22M$18.22M$19.08M
Operating income-$13.1M-$15.01M-$19.46M-$20.33M-$10.33M-$10.22M-$18.22M-$19.08M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$13.86M-$12.91M-$19.05M-$19.87M-$10.09M-$9.87M-$17.56M-$18.66M
Income taxes$0$0$0$0$0$0$0$0
Net income-$13.86M-$12.91M-$19.05M-$19.87M-$10.09M-$9.87M-$17.56M-$18.66M
Net income attributable to common shareholders-$13.86M-$12.91M-$19.05M-$19.87M-$10.09M-$9.87M-$17.56M-$18.66M
EBITDA-$13.1M-$15.01M-$19.46M-$20.33M-$10.33M-$10.22M-$18.22M-$19.08M
Basic earnings per share-$0.12-$0.11-$0.22-$0.33-$0.30-$0.30-$0.58-$0.62
Diluted earnings per share-$0.12-$0.11-$0.22-$0.33-$0.30-$0.30-$0.58-$0.62

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Relmada Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026

Relmada Therapeutics announced a conference call scheduled for November 12, 2026 at 4:30 PM ET to discuss third quarter 2026 financial results and business progress. The clinical-stage biotechnology company is advancing its lead candidates NDV-01 and sepranolone for oncology and central nervous system disorders, with NDV-01 progressing toward an IND filing expected by year-end 2026.

GlobeNewswire Inc.

Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference

Relmada Therapeutics announced that senior management will participate in one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference in Boston (September 8-10, 2026). The company is advancing its lead candidates NDV-01 and sepranolone through clinical development, with NDV-01 expected to reach IND filing by year-end 2026 and a Phase 3 RESCUE registrational program planned for initiation.

GlobeNewswire Inc.

Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes

Relmada Therapeutics, a clinical-stage biotechnology company, announced its addition to the Russell 2000® and Russell 3000® Indexes effective June 26, 2026. The company's CEO attributed the achievement to robust 12-month data for its lead candidate NDV-01 in NMIBC treatment and a well-capitalized balance sheet.

GlobeNewswire Inc.

Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026

Relmada Therapeutics announced presentations of NDV-01 clinical data at the American Urology Association conference in May 2026. Phase 2 data showed a 76% complete response rate at 12 months in high-risk non-muscle invasive bladder cancer patients. The company's Phase 3 'RESCUE' registrational program remains on track for mid-2026 initiation.

GlobeNewswire Inc.

Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026

Relmada Therapeutics announced a conference call scheduled for March 19, 2026 at 4:30 PM ET to discuss fourth quarter 2025 financial results and business progress. The clinical-stage biotechnology company is also presenting at the Leerink Partners Global Healthcare Conference and recently completed an oversubscribed $160 million private placement financing.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Sep 30, 20191-for-4reverse split
Aug 12, 20151-for-5reverse split